KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Before Jan 1, 2028 84%+8.0ptFührend unter 4 Optionen
Marktqualitat
47 / 100
Niedrige Qualität24h-Volumen
525,2 €
Liquidität
2382 €
Mittlere LiquiditätSpread
6.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 5 Minuten
14. Mai 26, 02:00 UTC1. Okt. 26, 03:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Will the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWill the FDA approve MDMA for PTSD?
KalshiWill the FDA approve cytisinicline for smoking cessation?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsRegeln
If the FDA approves CagriSema for marketing the named outcome, then the market resolves to Yes.
Abwicklung über:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Offene Märkte
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 18.288,2 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 5178,9 €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 weitere Ergebnisse
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Gesamtvolumen
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Gesamtvolumen
- 916.002,6 €
- 24h-Volumen
- 1515,1 €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 weitere Ergebnisse
- Gesamtvolumen
- 863.640,2 €
- 24h-Volumen
- 1039 €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Häufige Fragen
- Wie stehen die aktuellen Quoten für Will the FDA approve CagriSema??
- Kalshi bewertet Before Jan 1, 2028 mit 84% (Stand: 8. September 2026).
- Wann wird Will the FDA approve CagriSema? entschieden?
- Will the FDA approve CagriSema? soll am 1. Oktober 2026 entschieden werden.
- Wie wird Will the FDA approve CagriSema? abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA approves CagriSema for marketing the named outcome, then the market resolves to Yes.